Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study

PCV83 COMPARISON OF TREATMENT ADHERENCE AND PERSISTENCE WITH EDOXABAN VERSUS APIXABAN, DABIGATRAN, RIVAROXABAN, AND VITAMIN K ANTAGONIST IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN GERMANY: A PROPENSITY MATCHED COHORT STUDY

(2020) R. Wang et al.   VALUE IN HEALTH

Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review

(2019) Guillermo Prada-Ramallal et al.   BMC Medical Research Methodology

Effectiveness and Safety of Four Direct Oral Anticoagulants in Asians with Non-valvular Atrial Fibrillation

(2019) Yi-Hsin Chan et al.   CHEST

HAS-BLED score as a predictor of bleeding complications from catheter ablation of atrial fibrillation: A subanalysis of the Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registries

(2019) Koichi Inoue et al.   Journal of Cardiology

Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction

(2018) Simon Schwill et al.   BMC Family Practice

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

(2018) Jan Steffel et al.   EUROPEAN HEART JOURNAL

Global rising trends of atrial fibrillation: a major public health concern

(2018) Nileshkumar J Patel et al.   HEART

Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation

(2018) Nai-Fang Chi et al.   MEDICAL CARE

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients

(2018) Gregory Y.H. Lip et al.   STROKE

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study

(2015) Renate B Schnabel et al.   LANCET

Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials

(2014) S.K. Kakkos et al.   EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY

Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD

(2014) Z. Harel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation

(2014) Torben Larsen et al.   THROMBOSIS AND HAEMOSTASIS

Epidemiology of atrial fibrillation: European perspective

(2014) Massimo Zoni-Berisso et al.   Clinical Epidemiology

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients

(2012) T. Wilke et al.   EUROPACE

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries

(2011) H. Quan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation

(2010) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY